Biotech (XBI) is a publicly traded the market company. As of May 20, 2026, XBI trades at $131.56 with a market cap of $0 and a P/E ratio of 0.00. XBI moved +3.92% today. Year to date, XBI is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces XBI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded XBI stock?
Recent politician trading activity in XBI includes disclosures from Tommy Tuberville and David P. Joyce. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
XBI Key Metrics
Key financial metrics for XBI
Metric
Value
Price
$131.56
Market Cap
$0
P/E Ratio
0.00
EPS
$0.00
Dividend Yield
0.00%
52-Week High
$0.00
52-Week Low
$0.00
Volume
10.38M
Avg Volume
0
Revenue (TTM)
$0
Net Income
$0
Gross Margin
0.00%
Congressional Trades in XBI
Tommy Tuberville purchase XBI on May 8, 2024 (amount: $15.00K) for Joint.
David P. Joyce sale (full) XBI on Jun 30, 2023 (amount: $50.00K).
XBI analyst coverage data. Average price target: $0.00.
Common questions about XBI
Which politicians traded XBI stock?
Recent politician trading activity in XBI includes disclosures from Tommy Tuberville and David P. Joyce. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in XBI?
Yes. Rallies tracks politician and congressional stock disclosures for XBI, including reported purchases, sales, dates, owners, and trade amounts when available.
Is XBI research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XBI. It does not provide personalized investment advice.
